IVIg vs different infusion regimens of IVIG: Need for extra treatment
Primary treatment with intravenous immunoglobulin (IVIG) may leads to lower need for additional treatment (up to 6 months) compared with different infusion regimens of IVIG (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Primary treatment with intravenous immunoglobulin (IVIG) vs different infusion regimens of IVIG Need for additional treatment (up to 6 months) · people undergoing initial treatment for KD Primary treatment with intravenous immunoglobulin (IVIG) may leads to lower need for additional treatment (up to 6 months) compared with different infusion regimens of IVIG (low certainty). Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane Headline outcomes only | OR 0.29 [0.1, 0.88] | 4 studies · 1125 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Intravenous immunoglobulin for the treatment of Kawasaki disease 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.